Loading…

Evaluation of the “assessment for continuous treatment with hepatic arterial infusion chemotherapy” scoring system in patients with advanced hepatocellular carcinoma

Aim Sorafenib is the recommended standard of care for advanced hepatocellular carcinoma (HCC) patients. However, hepatic arterial infusion chemotherapy (HAIC) is a treatment option in Asia. We recently developed the assessment for continuous treatment with HAIC (ACTH) score to guide decision‐making...

Full description

Saved in:
Bibliographic Details
Published in:Hepatology research 2018-02, Vol.48 (3), p.E87-E97
Main Authors: Saeki, Issei, Yamasaki, Takahiro, Maeda, Masaki, Hisanaga, Takuro, Iwamoto, Takuya, Matsumoto, Toshihiko, Hidaka, Isao, Ishikawa, Tsuyoshi, Takami, Taro, Sakaida, Isao
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4172-b17e63c248d44bf421c34e1f21644df60917994cbd7474867efe7ba523e5dece3
cites cdi_FETCH-LOGICAL-c4172-b17e63c248d44bf421c34e1f21644df60917994cbd7474867efe7ba523e5dece3
container_end_page E97
container_issue 3
container_start_page E87
container_title Hepatology research
container_volume 48
creator Saeki, Issei
Yamasaki, Takahiro
Maeda, Masaki
Hisanaga, Takuro
Iwamoto, Takuya
Matsumoto, Toshihiko
Hidaka, Isao
Ishikawa, Tsuyoshi
Takami, Taro
Sakaida, Isao
description Aim Sorafenib is the recommended standard of care for advanced hepatocellular carcinoma (HCC) patients. However, hepatic arterial infusion chemotherapy (HAIC) is a treatment option in Asia. We recently developed the assessment for continuous treatment with HAIC (ACTH) score to guide decision‐making for continuous HAIC treatment. The purpose of this study was to validate the utility of the ACTH score in a dedicated cohort. Methods One hundred and thirty‐one patients with advanced HCC were enrolled in this study (90 in the training group and 41 in the validation group). The point score (range, 0–3) was calculated as follows: Child–Pugh score before HAIC (A = 0, B = 1), α‐fetoprotein (AFP) response (yes = 0, no = 1), and des‐γ‐carboxy prothrombin (DCP) response (yes = 0, no = 1). The AFP and DCP responses were assessed 2 weeks after HAIC induction; a positive response was defined as a reduction of ≥20% from the baseline. Results The DCP response in the validation group was significantly associated with treatment response, and the median survival time (MST) was longer in patients with an ACTH score ≤1 (15.9 months) than in those with a score ≥2 (7.0 months; P = 0.002). Survival in all patients showed significant stratification according to the ACTH score; the MSTs associated with scores of 0, 1, 2, and 3 points were 21.7, 14.4, 9.5, and 3.8 months, respectively. Conclusion The ACTH score can aid in the therapeutic assessment and continued treatment planning of HCC patients receiving HAIC.
doi_str_mv 10.1111/hepr.12932
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1914582420</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1914582420</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4172-b17e63c248d44bf421c34e1f21644df60917994cbd7474867efe7ba523e5dece3</originalsourceid><addsrcrecordid>eNp9kc1qFTEUx0NR7Idu-gAScFMKt-brZjJLKbdWKCjSgrshkznxpswkt0mm5e76IPUBfK0-iZlO68KF2SSQ3_mdk_wROqTkhJb1cQ2beEJZzdkO2qOqYgvCxY9X5cyVXEgu5C7aT-maEFoRJt6gXabkUkpF9tDv1a3uR51d8DhYnNeAH-8fdEqQ0gA-YxsiNsFn58cwJpwj6Px0cefyGpfWpdZgHTNEp3vsvB3TJDNrGELRRb3ZPt7_wsmE6PxPnLYpw1A4PFUWUZpNurvV3kA3K4OBvh97XXrraJwPg36LXlvdJ3j3vB-gq7PV5en54uLr5y-nny4WRtDy9JZWILlhQnVCtFYwargAahmVQnRWkppWdS1M21WiEkpWYKFq9ZJxWHZggB-go9m7ieFmhJSbwaVpHO2h_EBDayqWiglGCvrhH_Q6jNGX6QpV10pxQVWhjmfKxJBSBNtsoht03DaUNFOAzRRg8xRggd8_K8d2gO4v-pJYAegM3Lketv9RNeerb99n6R9_q6zG</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1999883418</pqid></control><display><type>article</type><title>Evaluation of the “assessment for continuous treatment with hepatic arterial infusion chemotherapy” scoring system in patients with advanced hepatocellular carcinoma</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Saeki, Issei ; Yamasaki, Takahiro ; Maeda, Masaki ; Hisanaga, Takuro ; Iwamoto, Takuya ; Matsumoto, Toshihiko ; Hidaka, Isao ; Ishikawa, Tsuyoshi ; Takami, Taro ; Sakaida, Isao</creator><creatorcontrib>Saeki, Issei ; Yamasaki, Takahiro ; Maeda, Masaki ; Hisanaga, Takuro ; Iwamoto, Takuya ; Matsumoto, Toshihiko ; Hidaka, Isao ; Ishikawa, Tsuyoshi ; Takami, Taro ; Sakaida, Isao</creatorcontrib><description>Aim Sorafenib is the recommended standard of care for advanced hepatocellular carcinoma (HCC) patients. However, hepatic arterial infusion chemotherapy (HAIC) is a treatment option in Asia. We recently developed the assessment for continuous treatment with HAIC (ACTH) score to guide decision‐making for continuous HAIC treatment. The purpose of this study was to validate the utility of the ACTH score in a dedicated cohort. Methods One hundred and thirty‐one patients with advanced HCC were enrolled in this study (90 in the training group and 41 in the validation group). The point score (range, 0–3) was calculated as follows: Child–Pugh score before HAIC (A = 0, B = 1), α‐fetoprotein (AFP) response (yes = 0, no = 1), and des‐γ‐carboxy prothrombin (DCP) response (yes = 0, no = 1). The AFP and DCP responses were assessed 2 weeks after HAIC induction; a positive response was defined as a reduction of ≥20% from the baseline. Results The DCP response in the validation group was significantly associated with treatment response, and the median survival time (MST) was longer in patients with an ACTH score ≤1 (15.9 months) than in those with a score ≥2 (7.0 months; P = 0.002). Survival in all patients showed significant stratification according to the ACTH score; the MSTs associated with scores of 0, 1, 2, and 3 points were 21.7, 14.4, 9.5, and 3.8 months, respectively. Conclusion The ACTH score can aid in the therapeutic assessment and continued treatment planning of HCC patients receiving HAIC.</description><identifier>ISSN: 1386-6346</identifier><identifier>EISSN: 1872-034X</identifier><identifier>DOI: 10.1111/hepr.12932</identifier><identifier>PMID: 28656680</identifier><language>eng</language><publisher>Netherlands: Wiley Subscription Services, Inc</publisher><subject>Adrenocorticotropic hormone ; Chemotherapy ; Decision making ; Hepatocellular carcinoma ; intra‐arterial infusion ; Liver cancer ; Patients ; Prothrombin ; scoring methods</subject><ispartof>Hepatology research, 2018-02, Vol.48 (3), p.E87-E97</ispartof><rights>2017 The Japan Society of Hepatology</rights><rights>2017 The Japan Society of Hepatology.</rights><rights>2018 The Japan Society of Hepatology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4172-b17e63c248d44bf421c34e1f21644df60917994cbd7474867efe7ba523e5dece3</citedby><cites>FETCH-LOGICAL-c4172-b17e63c248d44bf421c34e1f21644df60917994cbd7474867efe7ba523e5dece3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28656680$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Saeki, Issei</creatorcontrib><creatorcontrib>Yamasaki, Takahiro</creatorcontrib><creatorcontrib>Maeda, Masaki</creatorcontrib><creatorcontrib>Hisanaga, Takuro</creatorcontrib><creatorcontrib>Iwamoto, Takuya</creatorcontrib><creatorcontrib>Matsumoto, Toshihiko</creatorcontrib><creatorcontrib>Hidaka, Isao</creatorcontrib><creatorcontrib>Ishikawa, Tsuyoshi</creatorcontrib><creatorcontrib>Takami, Taro</creatorcontrib><creatorcontrib>Sakaida, Isao</creatorcontrib><title>Evaluation of the “assessment for continuous treatment with hepatic arterial infusion chemotherapy” scoring system in patients with advanced hepatocellular carcinoma</title><title>Hepatology research</title><addtitle>Hepatol Res</addtitle><description>Aim Sorafenib is the recommended standard of care for advanced hepatocellular carcinoma (HCC) patients. However, hepatic arterial infusion chemotherapy (HAIC) is a treatment option in Asia. We recently developed the assessment for continuous treatment with HAIC (ACTH) score to guide decision‐making for continuous HAIC treatment. The purpose of this study was to validate the utility of the ACTH score in a dedicated cohort. Methods One hundred and thirty‐one patients with advanced HCC were enrolled in this study (90 in the training group and 41 in the validation group). The point score (range, 0–3) was calculated as follows: Child–Pugh score before HAIC (A = 0, B = 1), α‐fetoprotein (AFP) response (yes = 0, no = 1), and des‐γ‐carboxy prothrombin (DCP) response (yes = 0, no = 1). The AFP and DCP responses were assessed 2 weeks after HAIC induction; a positive response was defined as a reduction of ≥20% from the baseline. Results The DCP response in the validation group was significantly associated with treatment response, and the median survival time (MST) was longer in patients with an ACTH score ≤1 (15.9 months) than in those with a score ≥2 (7.0 months; P = 0.002). Survival in all patients showed significant stratification according to the ACTH score; the MSTs associated with scores of 0, 1, 2, and 3 points were 21.7, 14.4, 9.5, and 3.8 months, respectively. Conclusion The ACTH score can aid in the therapeutic assessment and continued treatment planning of HCC patients receiving HAIC.</description><subject>Adrenocorticotropic hormone</subject><subject>Chemotherapy</subject><subject>Decision making</subject><subject>Hepatocellular carcinoma</subject><subject>intra‐arterial infusion</subject><subject>Liver cancer</subject><subject>Patients</subject><subject>Prothrombin</subject><subject>scoring methods</subject><issn>1386-6346</issn><issn>1872-034X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kc1qFTEUx0NR7Idu-gAScFMKt-brZjJLKbdWKCjSgrshkznxpswkt0mm5e76IPUBfK0-iZlO68KF2SSQ3_mdk_wROqTkhJb1cQ2beEJZzdkO2qOqYgvCxY9X5cyVXEgu5C7aT-maEFoRJt6gXabkUkpF9tDv1a3uR51d8DhYnNeAH-8fdEqQ0gA-YxsiNsFn58cwJpwj6Px0cefyGpfWpdZgHTNEp3vsvB3TJDNrGELRRb3ZPt7_wsmE6PxPnLYpw1A4PFUWUZpNurvV3kA3K4OBvh97XXrraJwPg36LXlvdJ3j3vB-gq7PV5en54uLr5y-nny4WRtDy9JZWILlhQnVCtFYwargAahmVQnRWkppWdS1M21WiEkpWYKFq9ZJxWHZggB-go9m7ieFmhJSbwaVpHO2h_EBDayqWiglGCvrhH_Q6jNGX6QpV10pxQVWhjmfKxJBSBNtsoht03DaUNFOAzRRg8xRggd8_K8d2gO4v-pJYAegM3Lketv9RNeerb99n6R9_q6zG</recordid><startdate>201802</startdate><enddate>201802</enddate><creator>Saeki, Issei</creator><creator>Yamasaki, Takahiro</creator><creator>Maeda, Masaki</creator><creator>Hisanaga, Takuro</creator><creator>Iwamoto, Takuya</creator><creator>Matsumoto, Toshihiko</creator><creator>Hidaka, Isao</creator><creator>Ishikawa, Tsuyoshi</creator><creator>Takami, Taro</creator><creator>Sakaida, Isao</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>201802</creationdate><title>Evaluation of the “assessment for continuous treatment with hepatic arterial infusion chemotherapy” scoring system in patients with advanced hepatocellular carcinoma</title><author>Saeki, Issei ; Yamasaki, Takahiro ; Maeda, Masaki ; Hisanaga, Takuro ; Iwamoto, Takuya ; Matsumoto, Toshihiko ; Hidaka, Isao ; Ishikawa, Tsuyoshi ; Takami, Taro ; Sakaida, Isao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4172-b17e63c248d44bf421c34e1f21644df60917994cbd7474867efe7ba523e5dece3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adrenocorticotropic hormone</topic><topic>Chemotherapy</topic><topic>Decision making</topic><topic>Hepatocellular carcinoma</topic><topic>intra‐arterial infusion</topic><topic>Liver cancer</topic><topic>Patients</topic><topic>Prothrombin</topic><topic>scoring methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Saeki, Issei</creatorcontrib><creatorcontrib>Yamasaki, Takahiro</creatorcontrib><creatorcontrib>Maeda, Masaki</creatorcontrib><creatorcontrib>Hisanaga, Takuro</creatorcontrib><creatorcontrib>Iwamoto, Takuya</creatorcontrib><creatorcontrib>Matsumoto, Toshihiko</creatorcontrib><creatorcontrib>Hidaka, Isao</creatorcontrib><creatorcontrib>Ishikawa, Tsuyoshi</creatorcontrib><creatorcontrib>Takami, Taro</creatorcontrib><creatorcontrib>Sakaida, Isao</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Hepatology research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Saeki, Issei</au><au>Yamasaki, Takahiro</au><au>Maeda, Masaki</au><au>Hisanaga, Takuro</au><au>Iwamoto, Takuya</au><au>Matsumoto, Toshihiko</au><au>Hidaka, Isao</au><au>Ishikawa, Tsuyoshi</au><au>Takami, Taro</au><au>Sakaida, Isao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of the “assessment for continuous treatment with hepatic arterial infusion chemotherapy” scoring system in patients with advanced hepatocellular carcinoma</atitle><jtitle>Hepatology research</jtitle><addtitle>Hepatol Res</addtitle><date>2018-02</date><risdate>2018</risdate><volume>48</volume><issue>3</issue><spage>E87</spage><epage>E97</epage><pages>E87-E97</pages><issn>1386-6346</issn><eissn>1872-034X</eissn><abstract>Aim Sorafenib is the recommended standard of care for advanced hepatocellular carcinoma (HCC) patients. However, hepatic arterial infusion chemotherapy (HAIC) is a treatment option in Asia. We recently developed the assessment for continuous treatment with HAIC (ACTH) score to guide decision‐making for continuous HAIC treatment. The purpose of this study was to validate the utility of the ACTH score in a dedicated cohort. Methods One hundred and thirty‐one patients with advanced HCC were enrolled in this study (90 in the training group and 41 in the validation group). The point score (range, 0–3) was calculated as follows: Child–Pugh score before HAIC (A = 0, B = 1), α‐fetoprotein (AFP) response (yes = 0, no = 1), and des‐γ‐carboxy prothrombin (DCP) response (yes = 0, no = 1). The AFP and DCP responses were assessed 2 weeks after HAIC induction; a positive response was defined as a reduction of ≥20% from the baseline. Results The DCP response in the validation group was significantly associated with treatment response, and the median survival time (MST) was longer in patients with an ACTH score ≤1 (15.9 months) than in those with a score ≥2 (7.0 months; P = 0.002). Survival in all patients showed significant stratification according to the ACTH score; the MSTs associated with scores of 0, 1, 2, and 3 points were 21.7, 14.4, 9.5, and 3.8 months, respectively. Conclusion The ACTH score can aid in the therapeutic assessment and continued treatment planning of HCC patients receiving HAIC.</abstract><cop>Netherlands</cop><pub>Wiley Subscription Services, Inc</pub><pmid>28656680</pmid><doi>10.1111/hepr.12932</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1386-6346
ispartof Hepatology research, 2018-02, Vol.48 (3), p.E87-E97
issn 1386-6346
1872-034X
language eng
recordid cdi_proquest_miscellaneous_1914582420
source Wiley-Blackwell Read & Publish Collection
subjects Adrenocorticotropic hormone
Chemotherapy
Decision making
Hepatocellular carcinoma
intra‐arterial infusion
Liver cancer
Patients
Prothrombin
scoring methods
title Evaluation of the “assessment for continuous treatment with hepatic arterial infusion chemotherapy” scoring system in patients with advanced hepatocellular carcinoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T23%3A39%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20the%20%E2%80%9Cassessment%20for%20continuous%20treatment%20with%20hepatic%20arterial%20infusion%20chemotherapy%E2%80%9D%20scoring%20system%20in%20patients%20with%20advanced%20hepatocellular%20carcinoma&rft.jtitle=Hepatology%20research&rft.au=Saeki,%20Issei&rft.date=2018-02&rft.volume=48&rft.issue=3&rft.spage=E87&rft.epage=E97&rft.pages=E87-E97&rft.issn=1386-6346&rft.eissn=1872-034X&rft_id=info:doi/10.1111/hepr.12932&rft_dat=%3Cproquest_cross%3E1914582420%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4172-b17e63c248d44bf421c34e1f21644df60917994cbd7474867efe7ba523e5dece3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1999883418&rft_id=info:pmid/28656680&rfr_iscdi=true